1
-
3
of
3
results (0.42 seconds)
Sort By:
-
Biosimilars, Part 3: Humira Biosimilar Launches
which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks ... which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks ...- Authors: Tony Pistilli, Greg Warren
- Date: Nov 2023
- Competency: External Forces & Industry Knowledge; Strategic Insight and Integration
- Publication Name: Health Watch
- Topics: Health & Disability; Health & Disability>Health care; Health & Disability>Health insurance; Public Policy; Public Policy; Public Policy
-
Biosimilars, Part 4: The Financial Impact
financial impact that could result from this year’s big event. Savings from biosimilars have accelerated ... financial impact that could result from this year’s big event. prescription drug costs, health care payment ...- Authors: Greg Warren, Tony Pistilli
- Date: Nov 2023
- Competency: External Forces & Industry Knowledge; Strategic Insight and Integration
- Publication Name: Health Watch
- Topics: Health & Disability; Health & Disability>Health care; Health & Disability>Health insurance; Public Policy; Public Policy; Public Policy
-
Accountable Care Organizations: An Untapped Opportunity
third-party, objective analysis when they are at the table bargain- 8 | september 2010 | Health Watch area ... health care costs if actuaries had been at the table with providers earlier in the process. ACO leadership ...- Authors: Jim Toole, Sara Teppema
- Date: Sep 2010
- Competency: External Forces & Industry Knowledge>External forces and business performance; Leadership>Thought leadership; Professional Values>Public interest representation; Strategic Insight and Integration
- Publication Name: Health Watch
- Topics: Enterprise Risk Management>Risk measurement - ERM; Enterprise Risk Management>Strategic risks; Health & Disability>Health care; Public Policy